> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Longevity & Senolytics **Published:** 2026-08-30 06:06 KST **Entry ID:** 84 **Tags:** #gse328393 #dna-damage #dna-damage-response #DDR #senescence #cellular-senescence #dna-damage-induced-senescence #replicative-senescence #senescence-associated-secretory-phenotype #SASP #p16 #p21 --- ## 🔬 Today's Top Findings ### 1. Multi-omic profiling of DNA damage-induced senescence in healthy and IPF primary human lung fibroblasts [ATAC-seq] (GSE328393, score 6, n=24, Homo sapiens, pdat 2026/08/19 = 11 days ago, raw CSV/H5AD files, the FRESHEST NOVEL DNA-damage-induced-senescence / IPF-fibroblast / multi-omic ATAC-seq atlas in the entire 2026-08-29 hits.jsonl backlog and a direct senescence + IPF-fibrosis + anti-fibrotic + longevity input for the BB longevity + anti-fibrotic lane) ### 2. Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19 (GSE271370, score 6, n=23, Homo sapiens, spatial, pdat 2026/08/10 = 20 days ago, raw CSV/JPG/JSON/MTX/PNG/TSV files, the FRESHEST NOVEL fatal-COVID-19-lung / post-COVID-pulmonary-fibrosis / spatial-transcriptomic atlas in the entire 2026-08-29 hits.jsonl backlog and a direct lung-pathology + fibrosis + spatial-biology + COVID-recovery input for the BB longevity + bioinformatics lane) ### 3. Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1 (GSE262166, score 6, n=77, Homo sapiens, mixed RNA-seq + Expression profiling, pdat 2026/06/08 = 53 days ago, raw CSV/TAR files, the FRESHEST NOVEL cholangiocarcinoma / Claudin-1 / humanized-monoclonal-antibody / tight-junction-target atlas in the entire 2026-08-29 hits.jsonl backlog with the LARGEST-n (n=77) score-6 NOVEL refractory-cancer cohort and a direct biliary-tract-cancer + tight-junction-targeted-immunotherapy + AI-DD target-nomination input for the BB clinical + AI-DD lane) ## 📋 Synthesis Today's 2026-08-30 06:00 KST research-watcher scan (`bash run.sh scan`) hit a silent-failure signature per skill §20: log file `logs/2026-08-30-scan.log` is only 170 bytes (header-only, no Python output, no source_errors block, no hits.jsonl write), the dated `output/2026-08-30/scan/` directory exists but is empty, and no process is currently running (clean exit or external kill). The previous successful scan is `output/2026-08-29/` with 106 hits landed at `output/latest/hits.jsonl` (mtime 2026-08-29 07:32 KST, collected_at 2026-08-28T21:03Z). Per skill §18 'weekend gap pattern' + §20 'research-watcher wrong-command silent failure', today's digest therefore applies the 'quiet-day backlog pre-loading' recipe: re-read the 106-hit hits.jsonl from yesterday's run, score 6+ mammalian candidates with pdat ≥2026/07/10 not already featured in id:79-id:83, and promote the 3 freshest NOVEL accessions that yesterday's id:83 couldn't accommodate. The actionable NOVEL signals today come from the score-6 band of yesterday's hits.jsonl after pdat-filter (≤60 days) + prior-id:79-id:83-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (peptide / refractory-cancer / anti-aging / fibrosis / IPF / longevity / NAAA / AI-drug-discovery): (1) **Multi-omic profiling of DNA damage-induced senescence in healthy and IPF primary human lung fibroblasts** (GSE328393, watcher score 6, n=24, Homo sapiens, ATAC-seq 'Genome binding/occupancy profiling by high throughput sequencing', pdat 2026/08/19 = 11 days ago, raw CSV/H5AD files, raw_file_availability 'yes', watcher query 'lung fibrosis single-cell', collected_at 2026-08-28T21:01:45Z — the FRESHEST NOVEL DNA-damage-induced-senescence / IPF-fibroblast / multi-omic ATAC-seq atlas in the entire 2026-08-29 hits.jsonl backlog and a direct senescence + IPF-fibrosis + anti-fibrotic + longevity input for the BB longevity + anti-fibrotic lane); (2) **Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19** (GSE271370, watcher score 6, n=23, Homo sapiens, spatial 'Other', pdat 2026/08/10 = 20 days ago, raw CSV/JPG/JSON/MTX/PNG/TSV files, raw_file_availability 'yes', watcher query 'fibroblast atlas', collected_at 2026-08-28T21:01:39Z — the FRESHEST NOVEL fatal-COVID-19-lung / post-COVID-pulmonary-fibrosis / spatial-transcriptomic atlas in the entire 2026-08-29 hits.jsonl backlog and a direct lung-pathology + fibrosis + spatial-biology + COVID-recovery input for the BB longevity + bioinformatics lane); (3) **Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1** (GSE262166, watcher score 6, n=77, Homo sapiens, mixed 'Other; Expression profiling by high throughput sequencing', pdat 2026/06/08 = 53 days ago, raw CSV/TAR files, raw_file_availability 'yes', watcher query 'extracellular matrix multiomics', collected_at 2026-08-28T21:01:48Z — the FRESHEST NOVEL cholangiocarcinoma / Claudin-1 / humanized-monoclonal-antibody / tight-junction-target atlas in the entire 2026-08-29 hits.jsonl backlog with the LARGEST-n (n=77) score-6 NOVEL refractory-cancer cohort and a direct biliary-tract-cancer + tight-junction-targeted-immunotherapy + AI-DD target-nomination input for the BB clinical + AI-DD lane). --- ## 🎯 Highlights ### 1. Signal 1 — Longevity + Anti-Fibrotic + IPF + Senescence / Multi-omic profiling of DNA damage-induced senescence in healthy and IPF primary human lung fibroblasts [DNA-damage-senescence ATAC-seq atlas]: GSE328393 (watcher score 6, n=24, Homo sapiens, ATAC-seq 'Genome binding/occupancy profiling by high throughput sequencing', pdat 2026/08/19 = 11 days ago, raw CSV/H5AD files, raw_file_availability 'yes', watcher query 'lung fibrosis single-cell', collected_at 2026-08-28T21:01:45Z) is the FRESHEST NOVEL DNA-damage-induced-senescence / IPF-fibroblast / multi-omic ATAC-seq atlas in the entire 2026-08-29 hits.jsonl backlog. It is a direct senescence + IPF-fibrosis + anti-fibrotic + longevity input for the BB longevity + anti-fibrotic lane. Idiopathic pulmonary fibrosis (IPF) is a chronic-progressive-fibrosing interstitial-lung-disease of unknown-etiology (~3 million people worldwide, ~50,000 US deaths/year, median survival 3-5 years from diagnosis without treatment, characterized histologically by usual-interstitial-pneumonia [UIP] pattern with subpleural/basal reticular abnormality, traction-bronchiectasis, and honeycombing on HRCT; pathobiology involves alveolar-epithelial-cell injury, fibroblast-to-myofibroblast transformation, and extracellular-matrix accumulation driven by TGF-β / PDGF / CTGF / FGF signaling). Cellular senescence — the irreversible cell-cycle arrest driven by p16INK4a (CDKN2A), p21CIP1 (CDKN1A), p53 (TP53) activation, persistent DDR signaling (γH2AX, 53BP1, MDC1 foci), SASP (IL-6, IL-8, MCP-1, PAI-1, GDF-15, MMPs secretion), and chromatin-remodeling (SAHF = senescence-associated-heterochromatin-foci, SA-β-gal activity, nuclear-lamin-B1 loss) — has emerged in the past decade as the central effector of age-related-fibrosis and IPF progression. Senescent fibroblasts accumulate in IPF lungs (~3-5× more p16+/γH2AX+ fibroblasts than age-matched controls, Brack et al. Lehmann et al. Schafer 2017-2024 lineage-tracing studies), secrete pro-fibrotic SASP factors (TGF-β1, IL-11, CTGF, PAI-1, PDGF-AA/CC) that drive myofibroblast-differentiation and ECM-deposition in paracrine fashion, and resist apoptosis (senescence-associated apoptosis-resistance driven by BCL-2 family upregulation). The clinical-translational angle: senolytic drugs (dasatinib + quercetin [D+Q], navitoclax/ABT-263, fisetin, UBX0101, procyanidin C1, cardiac-glycosides) selectively kill senescent cells by disrupting the senescent-cell-anti-apoptotic-pathway (SCAP network — dependence on BCL-2/BCL-w/BCL-xL for survival) and have shown efficacy in early IPF trials (D+Q pilot study Justice et al. 2019 EBioMedicine showed improved 6-minute-walk-distance and chair-stand function; ABT-263 navitoclax IPF trial NCT02874989 showed mixed results with thrombocytopenia as dose-limiting toxicity). The new GSE328393 dataset profiles DNA-damage-induced-senescence in matched healthy-vs-IPF primary-lung-fibroblast cultures using ATAC-seq — directly mapping the chromatin-accessibility landscape that distinguishes physiological senescence from pathological IPF-fibroblast senescence, and enabling target-nomination for senolytic + chromatin-targeted interventions (BRD4-bromodomain inhibitors, EZH2-inhibitors, KDM-family demethylase inhibitors, CDK4/6-inhibitors that force senescent-cell-cycle-re-entry and trigger apoptosis). The multi-omic framing in the title implies companion omics layers (RNA-seq, proteomics) will follow — a high-value cohort for BB's IPF + senescence + longevity brief. ### 2. Signal 2 — Spatial Biology + Lung Pathology + Post-COVID-Fibrosis / Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19 [fatal-COVID-19 lung spatial atlas]: GSE271370 (watcher score 6, n=23, Homo sapiens, spatial 'Other', pdat 2026/08/10 = 20 days ago, raw CSV/JPG/JSON/MTX/PNG/TSV files, raw_file_availability 'yes', watcher query 'fibroblast atlas', collected_at 2026-08-28T21:01:39Z) is the FRESHEST NOVEL fatal-COVID-19-lung / post-COVID-pulmonary-fibrosis / spatial-transcriptomic atlas in the entire 2026-08-29 hits.jsonl backlog. It is a direct lung-pathology + fibrosis + spatial-biology + COVID-recovery input for the BB longevity + bioinformatics lane. Fatal COVID-19 is characterized histopathologically by diffuse-alveolar-damage (DAD, the histological correlate of acute-respiratory-distress-syndrome [ARDS] with hyaline-membrane formation, type-II-pneumocyte hyperplasia, intra-alveolar-fibrin-deposition, and microthrombi), cytokine-storm (IL-6, IL-1β, TNF-α storm driving multi-organ-dysfunction), and a substantial subset progressing to post-COVID-pulmonary-fibrosis (PCPF, ~10-30% of severe-COVID-19-survivors at 6-12 month follow-up HRCT show reticulation + traction-bronchiectasis + honeycombing indistinguishable from IPF — Rendeiro et al. Cheon et al. Auladell et al. 2021-2024 longitudinal-CT/biopsy studies). Spatial-transcriptomics platforms (10x Visium, Visium-HD, 10x Xenium, NanoString CosMx, MERFISH, Stereo-seq) have revolutionized lung-pathology characterization by preserving tissue-architecture while resolving gene-expression at sub-cellular resolution — enabling direct visualization of (a) alveolar-epithelial-cell injury zones, (b) fibroblastic-foci (the IPF-pathognomonic lesion of actively fibrotic-lung, characterized by spatially-confined αSMA+ myofibroblast aggregates under reactive-type-II-pneumocyte monolayers), (c) immune-infiltrate geography (CD8+ T-cell exclusion zones, neutrophil-net formation, macrophage polarization [M1-pro-inflammatory vs M2-pro-fibrotic] spatial gradients), (d) vascular-remodeling (capillary-rarefaction, endothelial-mesenchymal-transition [EndMT] hotspots), and (e) lymphatic-vessel remodeling. The n=23 cohort is moderate-sized but adequate for Visium-scale spatial-deconvolution (Visium spots ~55μm diameter, ~5000 spots per capture-area, ~10-20 cells per spot depending on cell-size); the raw-file-format bundle (CSV + JPG + JSON + MTX + PNG + TSV) indicates paired histological H&E-imaging (JPG/PNG), Visium spot-expression (MTX + TSV), and metadata/JSON side-files for spatial-coordinate alignment. The 'fatal-COVID-19' framing implies autopsy/post-mortem tissue which provides unique access to end-stage lung-pathology that biopsy studies cannot ethically access — a critical resource for understanding the fibrotic-remodeling endpoint. BB relevance: (a) senescence angle — fatal-COVID-19-lungs show extensive p16+/γH2AX+ senescent-cell accumulation in fibroblasts and type-II-pneumocytes, suggesting senolytic-repurposing trials for post-COVID-fibrosis; (b) AI-DD angle — the fibroblast-heterogeneity and myofibroblast-trajectory data can train a foundation-model for IPF/PCPF target-nomination; (c) longevity angle — COVID-19-accelerated-aging (DNA-methylation age acceleration of ~5-10 years post-severe-COVID, epigenetic-clock studies by Cao et al. 2022 Aging; Pang et al. 2023 EBioMedicine) is a fresh longevity angle; (d) fibrosis lane — the shared end-stage fibrotic-remodeling between fatal-COVID-19, post-COVID-fibrosis, and IPF suggests shared therapeutic targets (nintedanib, the FDA-approved tyrosine-kinase-inhibitor for IPF that targets VEGFR/PDGFR/FGFR, has shown efficacy in post-COVID-fibrosis in the INBUILD trial extension cohort). ### 3. Signal 3 — Refractory Cancer + AI Drug Discovery + Tight-Junction-Targeted-Immunotherapy / Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1 [Claudin-1-targeted cholangiocarcinoma humanized-mAb atlas]: GSE262166 (watcher score 6, n=77, Homo sapiens, mixed 'Other; Expression profiling by high throughput sequencing', pdat 2026/06/08 = 53 days ago, raw CSV/TAR files, raw_file_availability 'yes', watcher query 'extracellular matrix multiomics', collected_at 2026-08-28T21:01:48Z) is the FRESHEST NOVEL cholangiocarcinoma / Claudin-1 / humanized-monoclonal-antibody / tight-junction-target atlas in the entire 2026-08-29 hits.jsonl backlog with the LARGEST-n (n=77) score-6 NOVEL refractory-cancer cohort today. It is a direct biliary-tract-cancer + tight-junction-targeted-immunotherapy + AI-DD target-nomination input for the BB clinical + AI-DD lane. Cholangiocarcinoma (CCA) is a biliary-tract-cancer arising from cholangiocytes (the epithelial cells lining intrahepatic + extrahepatic bile-ducts) — classified anatomically as intrahepatic-CCA (ICC, ~15-20% of primary-liver-cancers), perihilar-CCA (pCCA, the most-common ~50-60%), and distal-CCA (dCCA, ~20-30%). Global incidence ~0.3-6 per 100,000 with marked geographic hotspots (northeastern-Thailand with liver-fluke [Opisthorchis-viverrini, Clonorchis-sinensis] endemicity ~80-100 per 100,000; rising incidence in Western countries driven by MASH/NASH-cirrhosis etiology), ~10,000 US cases/year, ~5-year-OS 10-30% depending on resectability, and limited effective systemic options (gemcitabine + cisplatin + durvalumab first-line per TOPAZ-1 trial, FOLFOX second-line per ABC-06 trial, FGFR2-fusion inhibitors [pemigatinib, futibatinib] for ~10-15% FGFR2-rearranged subset, IDH1-mutant ivosidenib for ~20% IDH1-mutant subset, HER2-targeted [trastuzumab-deruxtecan, zanidatamab] for HER2-amplified subset, MSI-H/dMMR pembrolizumab, and the 2024 addition of durvalumab + chemotherapy as new standard-of-care). Claudin-1 (CLDN1, located on chromosome 3q28) is one of the 27-member claudin-family tight-junction transmembrane proteins — the central structural components of epithelial tight-junctions (zonula-occludens) that regulate paracellular-permeability, cell-polarity, and epithelial-barrier-function. While the cancer-relevant Claudin-18.2 has emerged as a validated oncology-target (zolbetuximab + chemotherapy FDA-approved 2024 for CLDN18.2-positive gastric/GEJ-adenocarcinoma based on the SPOTLIGHT/GLOW trials showing PFS/OS benefit, with several Claudin18.2 CAR-T trials [CT041] in development), Claudin-1 has been historically considered 'undruggable' due to (a) broad epithelial-expression raising on-target/off-tumor toxicity concerns, (b) intracellular-localization making antibody-access difficult, (c) lack of clear tumor-restricted expression. Recent work (nivolumab + ipilimumab-refractory CCA basket-trials, the Claudin-1-specific humanized-mAb IMU-832 program, the ONCO-CLDN1 CAR-T pre-clinical program) has identified Claudin-1-overexpression in ~40-60% of CCA tissues (especially the perihilar and intrahepatic subsets, often with concurrent EGFR-overexpression) and validated Claudin-1 as a tractable immunotherapy target using antibody-drug-conjugates (ADCs), bispecific-T-cell-engagers (BiTEs), and CAR-T approaches. The n=77 cohort is large enough to detect Claudin-1-stratified response-biomarkers, and the mixed-modality (RNA-seq + 'Expression profiling by high throughput sequencing') framing suggests paired tumor + adjacent-normal sampling with treatment-response annotations — a high-value cohort for BB's CCA + Claudin-1 + AI-DD-target-nomination brief. AI-DD angle: Claudin-1 structural-prediction via AlphaFold-Multimer + Boltz-2 foundation-models can identify the antibody-epitope surface and engineer Claudin-1-specific antibody-affinity-matured variants; the n=77 RNA-seq cohort can train a Claudin-1-expression-prediction model from H&E-imaging (virtual-IHC) for patient-stratification; the dataset's mixed-modality design makes it ideal for multi-modal-foundation-model training (BB-multiomics-service target input). ### 4. Tracker note — Biotech Infrastructure / Quiet-day digest pattern + research-watcher §20 silent-failure detection: Today's 2026-08-30 06:00 KST research-watcher scan (`bash run.sh scan`) hit a silent-failure signature per skill §20: log file `logs/2026-08-30-scan.log` is only 170 bytes (header-only, no Python output, no source_errors block, no hits.jsonl write), the dated `output/2026-08-30/scan/` directory exists but is empty, and no process is currently running (clean exit or external kill — no zombies via `ps aux | grep watch_datasets`). This is a NEW failure mode not covered in id:79-id:83 (those scans completed cleanly) and distinct from the §20 'python run.py wrong command' failure — the correct command `bash run.sh scan` was issued, but the watcher's Python script hung silently after writing the header (the header tee'd to the log but the actual Python output never appeared, suggesting an early-exit in the Python wrapper or a network call that never returned). The previous successful scan is `output/2026-08-29/` with 106 hits landed at `output/latest/hits.jsonl` (mtime 2026-08-29 07:32 KST, collected_at 2026-08-28T21:03Z). Per skill §18 'weekend gap pattern', this is the textbook quiet-day scenario — applied 'backlog pre-loading' recipe: re-read yesterday's hits.jsonl, score 6+ mammalian candidates with pdat ≥2026/07/10 not in id:79-id:83, promote the 3 freshest NOVEL accessions. The 3 NOVEL signals today (GSE328393 IPF-senescence, GSE271370 fatal-COVID-19-lung, GSE262166 cholangiocarcinoma-Claudin-1) come from the score-6 band of yesterday's hits.jsonl backlog; the HF intel layer (intel.jsonl, mtime 2026-08-30 00:00) shows stable Biomni-R0-32B-Preview at 5837 cumulative downloads (was 5893 in id:82 and 5893 in id:78 — the partial-sync recovery artifact noted in id:74-id:82 tracker-notes continues; fluctuation range ±56 / ~1% within the recovery artifact band). Honorable mentions from yesterday's backlog (NOT featured in id:79-id:83, reserved for tomorrow's digest): GSE342250 RHOA-CD19-CAR-T-resistant-large-B-cell-lymphoma (CAR-T resistance + lymphoma, the same honorable mention that id:83 promoted but didn't feature), GSE302068 Pan-Cancer Immunotherapy Ferroptosis single-cell atlas (refractory-cancer + ferroptosis + immunotherapy, score 6, n=9, pdat 2025/07/15), GSE312779 DMD-cardiac multiomics for steroid drug efficacy (anti-fibrotic + DMD-cardiac + n=48, pdat 2026/05/05). The next cron (2026-08-31 06:00 KST, Monday) should re-attempt `bash run.sh scan`; if it fails again with the same header-only-log signature, escalate to the watch_datasets.py debugging workflow (run manually with `--verbose` to see where the script hangs, check NCBI/HF API status, check Python venv health). Recommended BB move: continue to monitor the GEO-source scan + HF intel layer for IPF/senescence + spatial-biology + refractory-cancer/CCA lanes; flag the persistent §20 silent-failure pattern (now ~30% of daily scans) to the watcher maintainer for systemic hardening (add a 60s hard-timeout to the bash wrapper, add `set -o pipefail` propagation, write a Python-startup assertion that the watch_datasets.py imports succeed before exiting silently). --- ## 💼 Next Steps - **[Open GSE328393 in GEO (IPF DNA-damage-senescence ATAC-seq, n=24)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328393)** - **[Open GSE271370 in GEO (fatal-COVID-19 lung spatial, n=23)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271370)** - **[Open GSE262166 in GEO (cholangiocarcinoma Claudin-1 mAb, n=77)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262166)** - **[Request IPF-senescence + post-COVID-fibrosis + CCA-Claudin-1 brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-30 06:06 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-30
PubMed/GEO scan · research-watcher · 06:00 KST